The management of metastatic GIST: current standard and investigational therapeutics
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the
gastrointestinal tract. The majority of GISTs harbor gain of function mutations in either KIT or …
gastrointestinal tract. The majority of GISTs harbor gain of function mutations in either KIT or …
[HTML][HTML] Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer
The tropomyosin receptor kinase (TRK) family of receptor tyrosine kinases are encoded by
NTRK genes and have a role in the development and normal functioning of the nervous …
NTRK genes and have a role in the development and normal functioning of the nervous …
Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up
Highlights•This clinical practice guideline provides key recommendations on the
management of gastrointestinal stromal tumours.•Recommendations have been agreed …
management of gastrointestinal stromal tumours.•Recommendations have been agreed …
The ETS family of oncogenic transcription factors in solid tumours
Findings over the past decade have identified aberrant activation of the ETS transcription
factor family throughout all stages of tumorigenesis. Specifically in solid tumours, gene …
factor family throughout all stages of tumorigenesis. Specifically in solid tumours, gene …
NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022: Featured Updates to the NCCN Guidelines
Gastrointestinal stromal tumors (GIST) are the most common type of soft tissue sarcoma that
occur throughout the gastrointestinal tract. Most of these tumors are caused by oncogenic …
occur throughout the gastrointestinal tract. Most of these tumors are caused by oncogenic …
Gastrointestinal stromal tumor: challenges and opportunities for a new decade
C Serrano, S George - Clinical Cancer Research, 2020 - AACR
Gastrointestinal stromal tumor (GIST) provides a paradigm to evaluate new molecularly
targeted therapies and to identify structural and functional mechanisms for drug response …
targeted therapies and to identify structural and functional mechanisms for drug response …
[HTML][HTML] JSCO—ESMO—ASCO—JSMO—TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with …
Highlights•The PD-1 antibody pembrolizumab and the TRK inhibitors larotrectinib and
entrectinib recently received regulatory approval.•Such tumour-agnostic regulatory …
entrectinib recently received regulatory approval.•Such tumour-agnostic regulatory …
[HTML][HTML] Prognostic indicators for gastrointestinal stromal tumors: a review
H Zhang, Q Liu - Translational Oncology, 2020 - Elsevier
Gastrointestinal stromal tumors (GISTs) are potentially malignancies that can occur
anywhere in the digestive tract. Tyrosine kinase inhibitors (TKIs) such as imatinib have …
anywhere in the digestive tract. Tyrosine kinase inhibitors (TKIs) such as imatinib have …
A review of NTRK fusions in cancer
The family of the neurotrophic tropomyosin kinase receptors (NTRK or TRK) is a part of the
transmembrane tyrosine kinases responsible for neuronal development. The members of …
transmembrane tyrosine kinases responsible for neuronal development. The members of …
FGFR1 and NTRK3 actionable alterations in “Wild-Type” gastrointestinal stromal tumors
E Shi, J Chmielecki, CM Tang, K Wang… - Journal of translational …, 2016 - Springer
Abstract Background About 10–15% of adult, and most pediatric, gastrointestinal stromal
tumors (GIST) lack mutations in KIT, PDGFRA, SDHx, or RAS pathway components (KRAS …
tumors (GIST) lack mutations in KIT, PDGFRA, SDHx, or RAS pathway components (KRAS …